Author: Ming Zhong; Aijun Sun; Ting Xiao; Ge Yao; Ling Sang; Xia Zheng; Jinyan Zhang; Xuejuan Jin; Lei Xu; Wenlong Yang; Peng Wang; Kai Hu; Dingyu Zhang; Junbo Ge
Title: A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of a-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19) Document date: 2020_4_21
ID: mvsnybbo_41
Snippet: The copyright holder for this preprint . https://doi.org/10.1101/2020.04. 15.20066266 doi: medRxiv preprint colleagues [12] suggested that the replication of H5N1 influenza virus was impeded by overexpression of Cu/Zn superoxide dismutase (SOD1) , which was one of the antioxidation enzymes. Secondly, the anti-inflammation effect of ALA was verified by a series of clinical trials. ALA could significantly reduce levels of serum inflammatory cytokin.....
Document: The copyright holder for this preprint . https://doi.org/10.1101/2020.04. 15.20066266 doi: medRxiv preprint colleagues [12] suggested that the replication of H5N1 influenza virus was impeded by overexpression of Cu/Zn superoxide dismutase (SOD1) , which was one of the antioxidation enzymes. Secondly, the anti-inflammation effect of ALA was verified by a series of clinical trials. ALA could significantly reduce levels of serum inflammatory cytokines and improve symptoms of some severe patients (such as acute coronary syndrome, etc.) [21] [22] [23] [24] . Some clinical trials have been designed to dampen inflammatory responses. One clinical trial (ChiCTR2000029765) reported that neutralizing IL-6 with tocilizumab could quick control of high fever and respiratory symptoms in 21 patients with COVID-19 [11] , which revealed feasibility of anti-inflammation treatment for COVID-19.
Search related documents:
Co phrase search for related documents- acute coronary syndrome and coronary syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute coronary syndrome and high fever: 1, 2
- acute coronary syndrome and inflammatory cytokine: 1, 2, 3, 4, 5, 6
- acute coronary syndrome and inflammatory response: 1, 2, 3, 4, 5
- acute coronary syndrome and respiratory symptom: 1
- acute coronary syndrome and severe patient: 1, 2, 3, 4, 5, 6, 7, 8
- anti inflammation effect and inflammatory cytokine: 1
- anti inflammation effect and inflammatory response: 1, 2, 3, 4
- anti inflammation effect and influenza virus: 1
- anti inflammation treatment and clinical trial: 1, 2
- anti inflammation treatment and inflammatory response: 1
- clinical trial and coronary syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- clinical trial and high fever: 1, 2, 3, 4, 5
- clinical trial and inflammatory cytokine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- clinical trial and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60
- clinical trial and inflammatory response dampen: 1
- clinical trial and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
- clinical trial and respiratory symptom: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Co phrase search for related documents, hyperlinks ordered by date